Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Bristol Myers Squibb & Co

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program

Nektar Therapeutics (NASDAQ:NKTR) and Bristol Myers Squibb Co (NYSE:BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. The decision follows the results from pre-planned analyses of two late-stage studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer. A preplanned interim analysis…

Why Bristol Myers' Shares Are Trading Higher Today

Bristol Myers Squibb & Co (NYSE: BMY) has received positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis

Bristol Myers Squibb & Co (NYSE: BMY) has

inkl

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers Q4 Revenue, FY22 Sales Outlook Lag Consensus

Bristol Myers Q4 Revenue, FY22 Sales Outlook Lag Consensus

Bristol Myers Squibb & Co (NYSE: BMY) has posted

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

Bristol Myers Squibb

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play